全文获取类型
收费全文 | 3248篇 |
免费 | 177篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 49篇 |
妇产科学 | 82篇 |
基础医学 | 495篇 |
口腔科学 | 66篇 |
临床医学 | 260篇 |
内科学 | 687篇 |
皮肤病学 | 47篇 |
神经病学 | 226篇 |
特种医学 | 120篇 |
外科学 | 493篇 |
综合类 | 15篇 |
一般理论 | 1篇 |
预防医学 | 188篇 |
眼科学 | 43篇 |
药学 | 284篇 |
中国医学 | 14篇 |
肿瘤学 | 317篇 |
出版年
2023年 | 14篇 |
2022年 | 13篇 |
2021年 | 52篇 |
2020年 | 45篇 |
2019年 | 53篇 |
2018年 | 77篇 |
2017年 | 49篇 |
2016年 | 64篇 |
2015年 | 81篇 |
2014年 | 96篇 |
2013年 | 144篇 |
2012年 | 183篇 |
2011年 | 174篇 |
2010年 | 133篇 |
2009年 | 88篇 |
2008年 | 192篇 |
2007年 | 192篇 |
2006年 | 204篇 |
2005年 | 155篇 |
2004年 | 144篇 |
2003年 | 129篇 |
2002年 | 114篇 |
2001年 | 79篇 |
2000年 | 93篇 |
1999年 | 88篇 |
1998年 | 28篇 |
1997年 | 25篇 |
1996年 | 16篇 |
1995年 | 17篇 |
1994年 | 21篇 |
1993年 | 16篇 |
1992年 | 62篇 |
1991年 | 58篇 |
1990年 | 61篇 |
1989年 | 67篇 |
1988年 | 62篇 |
1987年 | 60篇 |
1986年 | 40篇 |
1985年 | 43篇 |
1984年 | 23篇 |
1983年 | 13篇 |
1982年 | 13篇 |
1980年 | 12篇 |
1979年 | 20篇 |
1978年 | 12篇 |
1977年 | 16篇 |
1976年 | 10篇 |
1974年 | 21篇 |
1968年 | 7篇 |
1967年 | 10篇 |
排序方式: 共有3440条查询结果,搜索用时 78 毫秒
1.
Susanna Zanutto Chiara Maura Ciniselli Antonino Belfiore Mara Lecchi Enzo Masci Gabriele Delconte Massimo Primignani Giulia Tosetti Marco Dal Fante Linda Fazzini Aldo Airoldi Marcello Vangeli Francesca Turpini Giovanni Giuseppe Rubis Passoni Paolo Viaggi Monica Arena Roberta Ilaria Olimpia Motta Anna Maria Cantù Cristiano Crosta Giuseppe De Roberto Francesca Iannuzzi Andrea Cassinotti Valentina Dall'Olio Laura Tizzoni Gabriella Sozzi Emanuele Meroni Luigi Bisanti Marco Alessandro Pierotti Paolo Verderio Manuela Gariboldi 《International journal of cancer. Journal international du cancer》2020,146(4):1164-1173
Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood based, to increase early CRC identification. MicroRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT-positive (FIT+) subjects in an Italian CRC screening program, we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real-time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort [EVC], 1121 cases). For each endoscopic lesion (low-grade adenoma [LgA], high-grade adenoma [HgA], cancer lesion [CL]), specific signatures were identified in the IVC and confirmed on the EVC. A two-miRNA-based signature for CL and six-miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the receiver operating characteristic curve (95% confidence interval) of the signatures were 0.644 (0.607–0.682), 0.670 (0.626–0.714) and 0.682 (0.580–0.785) for LgA, HgA and CL, respectively. A miRNA-based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most. 相似文献
2.
Simona Coco Simona Boccardo Marco Mora Vincenzo Fontana Irene Vanni Carlo Genova Angela Alama Sandra Salvi Maria Giovanna Dal Bello Silvia Bonfiglio Erika Rijavec Claudio Sini Giulia Barletta Federica Biello Franca Carli Zita Cavalieri Giovanni Burrafato Luca Longo Francesco Grossi 《Clinical breast cancer》2021,21(3):218-230.e6
IntroductionBreast cancer survivors are at increased risk of developing unrelated primary cancers, particularly lung cancer. Evidence indicates that sex hormones as well as a deregulation of DNA-repair pathways may contribute to lung cancer onset. We investigated whether the hormone status and expression of markers involved in DNA repair (BRCA1/2, ERCC1, and P53R2), synthesis (TS and RRM1), and cell division (TUBB3) might be linked to lung cancer risk.Patients and MethodsThirty-seven breast cancer survivors with unrelated lung cancer and 84 control subjects comprising women with breast cancer (42/84) or lung cancer (42/84) were enrolled. Immunohistochemistry on tumor tissue was performed. Geometric mean ratio was used to assess the association of marker levels with patient groups.ResultsEstrogen receptor was expressed in approximately 90% of the breast cancer group but was negative in the majority of the lung cancer group, a result similar to the lung cancer control group. Likewise, ER isoform β was weakly expressed in the lung cancer group. Protein analysis of breast cancer versus control had a significantly lower expression of BRCA1, P53R2, and TUBB3. Likewise, a BRCA1 reduction was observed in the lung cancer group concomitant with a BRCA2 increase. Furthermore, BRCA2 and TUBB3 increased in ipsilateral lung cancer in women who had previously received radiotherapy for breast cancer.ConclusionThe decrease of DNA-repair proteins in breast cancer could make these women more susceptible to therapy-related cancer. The increase of BRCA2 and TUBB3 in lung cancer from patients who previously received radiotherapy for breast cancer might reflect a tissue response to exposure to ionizing radiation. 相似文献
3.
4.
Ferulic acid chronic treatment exerts antidepressant-like effect: role of antioxidant defense system
5.
6.
7.
8.
9.
Marco Tagliamento Carlo Genova Giovanni Rossi Simona Coco Erika Rijavec Maria Giovanna Dal Bello 《Expert opinion on investigational drugs》2019,28(6):513-523
Introduction: The management of non-small cell lung cancer (NSCLC) has been substantially improved in the last few years; it has been revolutionized by a patient-tailored approach, especially in the oncogene addicted disease, and by novel combinations containing immune checkpoint inhibitors. However, chemotherapy still represents a mainstay that persists over the decades with limited novelties. Tubulin inhibitors belong to different sub-classes of drugs that share the capability to interfere with mitosis by a direct action on the microtubule system. Among them, taxanes and vinca alkaloids still have a prominent role in clinical practice.
Areas covered: This review summarizes the mechanisms of action, current role and future directions of microtubule targeting agents; we focus on investigational agents in phase I and II clinical trials.
Expert opinion: Chemotherapy maintains a pivotal role in the treatment of NSCLC. New generation agents that have the potential to overcome the mechanisms of resistance to the available drugs may provide new therapeutic opportunities. Predictive biomarkers derived from combination strategies and phase III studies are necessary going forward. 相似文献
10.